| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Contrast Media |
1 From the Department of Diagnostic and Interventional Radiology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany (M.G.); Rush North Shore Medical Center, Skokie, Ill (M.E.); Hôpital St Luc, Montreal, Quebec, Canada (P.P.); London Health Sciences Center, London, Ontario, Canada (E.O.); Hospital Italiano, Buenos Aires, Argentina (H.B.); Royal Adelaide Hospital, Adelaide, Australia (J.T.); University of Florida/Shands-Jacksonville, Jacksonville, Fla (D.S.); University of Iowa Hospital and Clinics, Iowa City, Iowa (M.S.); University of Pennsylvania School of Medicine, Philadelphia, Pa (E.R.M.); St Luke's Medical Center, Milwaukee, Wis (R.B.); Brigham and Women's Hospital, Boston, Mass (E.K.Y.); Berlex Laboratories, Montville, NJ (K.S.); and EPIX Medical, Cambridge, Mass (R.M.W.). Received May 30, 2004; revision requested June 8; revision received September 9; accepted December 16. Address correspondence to M.G., University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany (e-mail: mathias{at}goyen.de).
PURPOSE: To evaluate prospectively the safety and effectiveness of aortoiliac magnetic resonance (MR) angiography enhanced with MS-325 (gadofosveset trisodium) at a dose of 0.03 mmol/kg; effectiveness was defined as accuracy relative to the reference standard, conventional angiography.
MATERIALS AND METHODS: Study was approved by institutional review boards of participating institutions, and required national approvals were obtained. Study protocol conformed to Good Clinical Practice guidelines, and informed patient consent was obtained. Patients with known or suspected peripheral vascular disease received 0.03 mmol/kg MS-325 for aortoiliac MR angiography. They were also examined with conventional angiography. MS-325–enhanced MR was evaluated for safety and effectiveness. Along with unenhanced two-dimensional time-of-flight MR angiography, it was compared with conventional angiography for presence of vascular stenosis. Student t tests were used to identify significant improvement in diagnostic sensitivity, specificity, and accuracy, as well as quantitative characterization of stenoses by three blinded readers. Correlations between readers of conventional angiograms were calculated and compared with MR results.
RESULTS: In 174 patients, MS-325–enhanced MR angiography showed significant improvement (P 
.001) in sensitivity, specificity, and accuracy for diagnosis of clinically significant (
50%) stenosis, compared with unenhanced MR. For all readers, areas under the receiver operating characteristic curve for both quantitative and qualitative measures of significant disease increased (P < .001) for MS-325–enhanced MR compared with time-of-flight MR. All readers also expressed higher confidence in diagnosis (P < .001) and found fewer images uninterpretable with MS-325 enhancement. All measures of interpretation accuracy approached corresponding measures of correlation between readers of conventional angiograms. Incidence of severe and serious adverse events with MS-325 was low. No patients were withdrawn from study due to adverse events or abnormalities in laboratory results. There were no clinically important trends in findings at hematology, blood chemistry, urinalysis, electrocardiography, or physical examination.
CONCLUSION: MR angiography with MS-325 provides significant improvement in effectiveness over unenhanced MR (and minimal and transient side effects) at a dose of 0.03 mmol/kg and was safe and effective for MR evaluation of patients with aortoiliac occlusive disease.
© RSNA, 2005
This article has been cited by other articles:
|
|
 |
|
  D. R. Hadizadeh, J. Gieseke, S. H. Lohmaier, K. Wilhelm, J. Boschewitz, F. Verrel, H. H. Schild, and W. A. Willinek Peripheral MR Angiography with Blood Pool Contrast Agent: Prospective Intraindividual Comparative Study of High-Spatial-Resolution Steady-State MR Angiography versus Standard-Resolution First-Pass MR Angiography and DSA Radiology, September 3, 2008; (2008) 2492072033. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Ersoy and F. J. Rybicki MR Angiography of the Lower Extremities Am. J. Roentgenol., June 1, 2008; 190(6): 1675 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Soulez, M. Pasowicz, G. Benea, L. Grazioli, J. P. Niedmann, M. Konopka, P. C. Douek, G. Morana, F. K. W. Schaefer, A. Vanzulli, et al. Renal Artery Stenosis Evaluation: Diagnostic Performance of Gadobenate Dimeglumine-enhanced MR Angiography--Comparison with DSA Radiology, April 1, 2008; 247(1): 273 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bosch, K.-F. Kreitner, M. F. Peirano, S. Thurner, K. Shamsi, and E. C. Parsons Jr. Safety and Efficacy of Gadofosveset-Enhanced MR Angiography for Evaluation of Pedal Arterial Disease: Multicenter Comparative Phase 3 Study Am. J. Roentgenol., January 1, 2008; 190(1): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thurnher, S. Miller, G. Schneider, C. Ballarati, G. Bongartz, C. U. Herborn, S. Schoenberg, M. A. Cova, G. Morana, K. Niazi, et al. Diagnostic Performance of Gadobenate Dimeglumine Enhanced MR Angiography of the Iliofemoral and Calf Arteries: A Large-Scale Multicenter Trial Am. J. Roentgenol., November 1, 2007; 189(5): 1223 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nikolaou, H. Kramer, C. Grosse, D. Clevert, O. Dietrich, M. Hartmann, P. Chamberlin, S. Assmann, M. F. Reiser, and S. O. Schoenberg High-Spatial-Resolution Multistation MR Angiography with Parallel Imaging and Blood Pool Contrast Agent: Initial Experience Radiology, December 1, 2006; 241(3): 861 - 872. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
